Comparative Pharmacology
Head-to-head clinical analysis: BRIXADI versus PIVYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIXADI versus PIVYA.
BRIXADI vs PIVYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.
Pivya (pivmecillinam) is a prodrug of mecillinam, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 2 (PBP2), leading to defective cell wall formation and cell death.
Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.
1200 mg orally once daily.
None Documented
None Documented
Terminal half-life approximately 470–500 hours (~20 days) following intramuscular injection, allowing weekly or monthly dosing.
Terminal elimination half-life of 3-4 hours in patients with normal renal function; may be prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal (80–90%) as unchanged drug; renal elimination accounts for <5% of the dose.
Primarily renal excretion as unchanged drug (approximately 70-80%); biliary/fecal excretion accounts for 10-15%.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist